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Objectives

NK cells are a type of innate lymphocyte that specializes in killing
of virally infected cells and tumor cells. Adoptive NK therapy has
been successful for the treatment of many types of liquid tumors,
including leukemia and lymphomas. However, due to the
suppressive tumor microenvironment (TME), NK cells are not
effective for targeting solid tumors. Oncolytic virus delta24RGD
has been shown to induce inflammation in the TME following
local injection. In addition, NK cells have been shown to be
effective in eliminating adenovirus-infected cells. Therefore, this
study will examine whether the combination of delta24RGD and
NK cells can be effective for treating highly aggressive solid
tumors and what the mechanisms behind the synergy is. This
study will focus on investigating 1) the phenotypic changes in
tumors following infection by the oncolytic virus, 2) the
phenotypic and functional changes in NK cells following
exposure to infected tumor cells, 3) the changes to the TME
following viral infection of the tumor cells and how these changes
can affect NK function and persistence. The results from this
study can lay the foundation for potentially moving this treatment
into the clinic. In addition, the mechanistic discoveries can be
helpful for future genetic engineering of oncolytic viruses and NK
cells be even more effective at targeting solid tumors.

1.1 Aim 1: investigate the phenotypic changes in tumor cells after infection
by oncolytic viruses.
We will characterize the change in surface ligand expression in the infected
tumor cells including upregulation of stress ligand expression and
downregulation of MHC expression. In addition, we will knock out and/or
block the ligands that have an expression level change to see if it can negate
the synergistic effect of the combination therapy.

Materials
PDAC and glioblastoma tumor cells:
For this aim, as a proof-of-principle experiment, we will be using glioblastoma
(GB) and pancreatic ductal adenocarcinoma (PDAC) as tumor models for
aggressive solid tumors because these two are one of the most difficult tumors
to target with immunotherapy so far. The GB cell lines used are U87, which is
an example of an adherent and differentiated GB cell line and GSC 8-11, which
is an example of a glioma stem cell cell line. Both cell lines are used to
determine whether the combination therapy can target both the main GB tumor
and the GB stem cells. For PDACs, we will be using CAPAN1 as an example
of a slow-growing PDAC model and BXPC3 as an example of a fast-growing
PDAC model to cover a wider variety of PDAC types.

NK cells:
All the NK cells used in this aim are cord blood NK cells that are isolated from
fresh cord blood, expanded with IL-2, and stimulated with UAPC every 7-8
days. All NKs are used between day 11-28 after isolation to ensure optimum
and consistent cytotoxicity quality and reflect the clinical use of cord blood
NKs.

Virus:
All delta24RGD and delta24RGDOX viruses are synthesized by the GomezManzano lab and Fueyo lab
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1.2 Aim 2: Determine the phenotypic and functional changes in NK cells
when co-incubated with tumor cells infected by the oncolytic virus.
We will investigate the changes in the cytotoxic capabilities and
activation/exhaustion status of NK cells induced by the oncolytic virus in vitro.
We will then confirm the results in vivo.
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1.3 Aim 3: Determine the change in TME in vivo under the combination
treatment and its long-term effect on the activity of adoptively transferred
NK cells.
We will measure the changes in immune cell infiltration and cytokine secretion
in the tumor microenvironment in the primary tumor as well as the noninjected secondary tumor. In addition, we will determine the ability of the
adoptively transferred NK cells to infiltrate the tumor, the exhaustion profile of
those NK cells and duration of persistence after initial injection.

The experiments described in this proposal will characterize the efficacy of
combination therapy with oncolytic virus and NK cells and provide a
mechanistic explanation of it. The findings of this study may serve as the
preclinical data to justify the use of oncolytic viruses with NK cells in the
clinic to treat aggressive solid tumors that were previously resistant to
immunotherapy.

60

80

100

120

Time (hr)

Viral dose: 0.5 MOI
E:T ratio=1:10

Viral dose: 0.5 MOI
E:T ratio=1:20

Normalized GFP Total Integrated Intensity

Background

350
300
250

Tumor only
0.05 MOI Virus only

200
150
100

IL-21 sec NK only
50

10 20 30 40 50 60 70 80 90 100 110 120 130 140

Time (hr)

BXPC3 - day 3

NK-only treatment

Virus-only treatment

NK+Virus treatment

Green = tumor cells
Red = dead-cell stain
The experiments described provided significant data towards the idea of
combination therapy between oncolytic adenoviruses and natural killer cells.
As expressed in the first graph that explores the cell line BXPC3, our low viral
dose does insignificant killing against our tumor cells. In comparison, when we
add our NK cells to our tumor cells, we are presented with significant killing
but around the 60-hour mark, our NK cells slow down and eventually and stop
killing. However, when we combine the NK cells with our virus, we are able to
see a synergistic effect in which killing does not stop and rather continues on
past 100 hours. As depicted on the images above, we are able see a grand
difference between the tumor untreated in comparison to the other three
treatments. It is important to note how our pictures support the information
presented on the graph. After trying the same procedure with a different cell
line (CAPAN1), we were able to see the same synergistic effect in which the
combination between NK cells and oncolytic viruses does a greater killing of
tumor cells.

After analyzing the previous graphs that encompass three different cell lines
and express similar results to the same procedure, we are able to conclude that
the combination between oncolytic adenoviruses and natural killer cells is more
efficient against treating highly aggressive solid tumors. Additionally, we are
able to conclude that oncolytic viruses, by themselves are highly inefficient
against tumor cells. Lastly, NK cells are better at eliminating tumor cells, but
overtime lose their efficacy. The findings from this research allow for questions
regarding the behavioral and phenotypic changes in NK cells after they have
been co-incubated with tumor cells that have been exposed to the oncolytic
virus. The findings from these experiments can potentially allow for further
exploration which includes but is not limited to new therapy for solid tumors
and testing on mice. Additionally, these findings could be used towards
preclinical data to justify the use of combination therapy between oncolytic
adenoviruses and NK cells in a clinical setting where it could be used to treat
solid tumors previously resistant to immunotherapy.
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Conclusions

In the graph above, we are presenting the results of a
similar procedure as the one realized on the BXPC3 and
CAPAN1 cell lines. In comparison to the graphs shown
prior to this one, the Y axis represents the normalized
GFP intensity which is a straight correlation to the
number of GFP+ GSC tumor cells alive. As depicted in
the graph, and in accordance with our previous graphs,
the addition of our virus did no significant, with some of
our data points overlapping with our tumor only
treatment. It is also important to note how our virus only
treatment follows a similar, if not, identical pattern as
our control. However, with the addition of our IL-21
secreting NK cells we can see a constant killing of
tumor cells that denotes a massive difference in
comparison to the tumor only treatment. However, when
we combine our Delta24RBG virus and IL21 secreting
NK cells, we are able to recognize a synergistic effect in
which the glioma stem cells are killed efficiently,
eventually reaching an integrated intensity that
approximates zero.
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